Erectile Dysfunction Market Report (2022 to 2030) - Pfizer Inc., Eli Lilly and Company, Sanofi, Auxilium Pharmaceuticals, Inc., Bayer AG and Valenta Pharmaceuticals

Erectile Dysfunction Market Report (2022 to 2030) – Pfizer Inc., Eli Lilly and Company, Sanofi, Auxilium Pharmaceuticals, Inc., Bayer AG and Valenta Pharmaceuticals

Growth Plus Reports

Growth Plus Reports

Pune, 01 Dec. 2022 (GLOBE NEWSWIRE) — According to the latest report published by Growth Plus Reports, the erectile dysfunction market it is expected that the clock US$4.30 billion by 2030 and grow to a 8.3% CAGR during the forecast period. Due to the increase in cases of erectile dysfunction due to the worldwide increase in the elderly population. This exclusive information is published by Growth Plus Reports in its report titled “Erectile Dysfunction Market – Global Outlook and Forecast 2022-2030”

Download PDF Brochure of Erectile Dysfunction Market Size – Impact of COVID-19 and Global Analysis with Strategic Developments on:

Growth engines

The adoption of a sedentary lifestyle and the stress that comes with it, the growing geriatric population, and the comorbidity of erectile dysfunction with heart disease and diabetes are a few factors propelling the dysfunction medicine industry. erectile (DE). The likelihood of erectile dysfunction is greatly increased by a sedentary lifestyle, drunkenness and smoking. Increased acceptability of such harmful lifestyle choices could drive market expansion.

The global erectile dysfunction market has been analyzed from three angles: drug, distribution channel and region.

Excerpts from “By drug segmentation”

By Type, the global erectile dysfunction market is segmented into:

  • Sildenafil

  • Tadalafil

  • Vardenafil

  • Alprostadil

  • Avanafil

  • Udenafil

Sildenafil (Viagra) is the most popular drug used as an initial treatment for erectile dysfunction. One hour before intercourse, sildenafil (Viagra) is most effective when taken on an empty stomach. If you suffer from mild to moderate erectile dysfunction, it remains effective for at least four to five hours. Lupine obtained approval from the United States Food and Drug Administration (FDA) in March 2019 to market its Sildenafil tablets USP, 25 mg, 50 mg and 100 mg as a generic alternative to Viagra tablets from Pfizer Inc., 25mg, 50mg, and 100mg. Thus, throughout the projection period, the segment is expected to grow due to the success of Viagra (sildenafil citrate) in the treatment of erectile dysfunction.

Excerpts from ‘Segmentation by region’

Based on region, the global erectile dysfunction market has been segmented into:

  • North America

  • Europe

  • Asia Pacific

  • Rest of the world

During the projected period, the erectile dysfunction drugs market in Asia Pacific is expected to grow rapidly. The introduction of new items has contributed to the growth of the region. For example, iX Biopharma said in May 2020 that it would supply Wafesil and Silcap to Australia via telemedicine to treat an adult patient with erectile dysfunction.

Browse Detailed Abstract of Research Report with TOC:

Excerpts from “Competitive Landscape”

The key players operating in the global erectile dysfunction market are:

  • Pfizer Inc.

  • Eli Lilly and company

  • Viatris Specialty LLC

  • Petros Pharmaceuticals Inc.

  • Bayer AG

  • Teva Pharmaceutical Industries Ltd.

  • Sanofi

  • LIVE, Inc.

  • Aid Pharmaceuticals, Inc.

  • Valenta Pharmaceuticals

  • Vigonvita Life Sciences

  • EMS

  • RDC Clinical Pty Ltd.

  • Futura Medical



    1. Market ecosystem

    2. Schedule under study

      1. Historical years – 2020

      2. Base year – 2021

      3. Planned years – 2022 to 2030

    3. Currency used in the report


    1. Research approach

    2. Data collection methodology

    3. Information source

      1. Secondary sources

      2. Primary sources

    4. Market estimation approach

      1. From bottom to top

      2. From top to bottom

    5. Market Forecast Model

    6. Limits and assumptions


    1. Current market trends (COVID-19 outlook)

    2. Key players and competitive positioning (2021)


    1. Drivers

    2. Constraints/Challenges

    3. Opportunities


    1. Sildenafil

    2. Tadalafil

    3. Vardenafil

    4. Alprostadil

    5. Avanafil

    6. Udenafil


    1. Hospital pharmacy

    2. Retail pharmacy

    3. Online pharmacy


  • Fueled by free analyst hours and expert interviews with every report

  • Comprehensive quantitative and qualitative information at segment and sub-segment level

  • Trends and perspectives of the impact of Covid 19

  • Granular information at global/regional/country level

  • In-depth insights into market dynamics (drivers, restraints, opportunities) and business environment

  • Global coverage of the competitive landscape

  • Winning imperatives

  • Comprehensive coverage of “strategic developments” recorded by major market players


  • Distributor Landscape Assessment

  • Pricing information

  • Customer evaluation

  • Analysis of investments and initiatives

  • ‘Company Profile’ of key players

Directly purchase a premium copy of the Erectile Dysfunction Market Growth Report (2022-2030) at:

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge services company. We are proud members of the EPhMRA (European Pharmaceutical Marketing Research Association).

The Growth Plus portfolio of services leverages our core capabilities in secondary and primary research, market modeling and forecasting, benchmarking, analysis and strategy formulation to help clients create scalable solutions and breakthroughs that set them up for future growth and success.

We have been recognized by the prestigious CEO Magazine as “2020’s Most Innovative Healthcare Market Research Company”.

CONTACT: Manan Sethi Director, Market Insights Email: Phone no: +91 96545 76783 Web:  Follow Us: LinkedIn | Twitter

#Erectile #Dysfunction #Market #Report #Pfizer #Eli #Lilly #Company #Sanofi #Auxilium #Pharmaceuticals #Bayer #Valenta #Pharmaceuticals

Leave a Comment

Your email address will not be published. Required fields are marked *